Article Details

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients

Retrieved on: 2022-11-01 11:10:29

Tags for this article:

Click the tags to see associated articles and topics

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients. View article details on HISWAI: https://www.elpasoinc.com/vigil-neuroscience-receives-fda-fast-track-designation-for-vgl101-for-the-treatment-of-patients/article_b04034d3-2539-5744-9f61-5b0cc1215560.html

Excerpt

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to ...

Article found on: www.elpasoinc.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up